Literature DB >> 12111814

Platelet-activating factor induces permeability transition and cytochrome c release in isolated brain mitochondria.

Mark A Parker1, Haydee E P Bazan, Victor Marcheselli, Elena B Rodriguez de Turco, Nicolas G Bazan.   

Abstract

Platelet-activating factor (PAF), a potent bioactive phospholipid implicated in neuronal excitotoxic death, was assessed as a mediator of brain mitochondrial dysfunction. Carbamyl PAF, a non-hydrolyzable PAF analog, added to neurons in culture resulted in decreased mitochondrial membrane potential (DeltaPsi(M)) as measured by the DeltaPsi(M)-sensitive fluorophore 5,5', 6,6'-tetrachloro-1, 1', 3,3'-tetraethylethylbenzimidazolo-carbocyanide iodide (JC-1). To investigate whether PAF has a direct effect on the mitochondria, the mediator was added to rat brain mitochondria preparations and an increase in the permeability of the mitochondrial membrane, termed permeability transition (PT), and cytochrome c release were measured. We report that PAF causes both dose-dependent PT and cytochrome c release from isolated mitochondria. Furthermore, the selective PAF antagonist tetrahydro-4,7,8,10 methyl-1 (chloro-2 phenyl)-6 (methoxy-4 phenyl-carbamoyl)-9 pyrido [4',3'-4,5] thieno [3,2-f] triazolo-1,2,4 [4,3-a] diazepine-1,4 (BN50730), which has affinity for intracellular binding sites, and the peripheral benzodiazepine receptor ligands 7-chloro-5- [4'-chlorophenyl]-1,3-dihydro-1-methyl-2H-1,4-benzodiazepin-2-one (Ro5-4864) and 1-(-2-chlorophenyl)-N-methyl-N-(1-methylpropyl)-3-isoquinolinecarboxamide (PK11195), inhibit PAF induction of PT and cytochrome c release. These results suggest that PAF excitotoxicity involves, at least in part, alterations of the mitochondrial membrane. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12111814     DOI: 10.1002/jnr.10235

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  8 in total

Review 1.  Translocator protein (18 kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders.

Authors:  Rainer Rupprecht; Vassilios Papadopoulos; Gerhard Rammes; Thomas C Baghai; Jinjiang Fan; Nagaraju Akula; Ghislaine Groyer; David Adams; Michael Schumacher
Journal:  Nat Rev Drug Discov       Date:  2010-12       Impact factor: 84.694

Review 2.  Translocator protein (18 kDa) TSPO: an emerging therapeutic target in neurotrauma.

Authors:  Vassilios Papadopoulos; Laurent Lecanu
Journal:  Exp Neurol       Date:  2009-05-04       Impact factor: 5.330

3.  Deficiency of phospholipase A2 group 7 decreases intestinal polyposis and colon tumorigenesis in Apc(Min/+) mice.

Authors:  Changxin Xu; Ethan C Reichert; Tomoyuki Nakano; Mariah Lohse; Alison A Gardner; Mónica P Revelo; Matthew K Topham; Diana M Stafforini
Journal:  Cancer Res       Date:  2013-01-29       Impact factor: 12.701

Review 4.  Mitochondrial apoptosis and the peripheral benzodiazepine receptor: a novel target for viral and pharmacological manipulation.

Authors:  Maria Castedo; Jean-Luc Perfettini; Guido Kroemer
Journal:  J Exp Med       Date:  2002-11-04       Impact factor: 14.307

5.  Prognostic role of translocator protein and oxidative stress markers in chronic lymphocytic leukemia patients treated with bendamustine plus rituximab.

Authors:  Aniello DE Rosa; Silvia Zappavigna; Maria Rosaria Villa; Salvatore Improta; Elena Cesario; Lucia Mastrullo; Michele Caraglia; Paola Stiuso
Journal:  Oncol Lett       Date:  2014-12-19       Impact factor: 2.967

6.  Oxidative imbalance and anxiety disorders.

Authors:  Krolow R; Arcego D M; Noschang C; Weis S N; Dalmaz C
Journal:  Curr Neuropharmacol       Date:  2014-03       Impact factor: 7.363

7.  Platelet Activating Factor Enhances Synaptic Vesicle Exocytosis Via PKC, Elevated Intracellular Calcium, and Modulation of Synapsin 1 Dynamics and Phosphorylation.

Authors:  Jennetta W Hammond; Shao-Ming Lu; Harris A Gelbard
Journal:  Front Cell Neurosci       Date:  2016-01-08       Impact factor: 5.505

8.  Regulation of the mitochondrial permeability transition pore by the outer membrane does not involve the peripheral benzodiazepine receptor (Translocator Protein of 18 kDa (TSPO)).

Authors:  Justina Šileikytė; Elizabeth Blachly-Dyson; Randall Sewell; Andrea Carpi; Roberta Menabò; Fabio Di Lisa; Fernanda Ricchelli; Paolo Bernardi; Michael Forte
Journal:  J Biol Chem       Date:  2014-04-01       Impact factor: 5.157

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.